Knee (n=28) | Ankle (n=13) | Knee and ankle (n=41) | |||||||
---|---|---|---|---|---|---|---|---|---|
SpA (n=8) | RA (n=13) | CA (n=7) | SpA (n=5) | RA (n=7) | CA (n=1) | SpA (n=13) | RA (n=20) | CA (n=8) | |
Perientheseal fluid/oedema | 5 (62.5) | 9 (69.2) | 7 (100) | 3 (75.0) | 6 (85.7) | 1 (100) | 8 (66.7) | 15 (75.0) | 8 (100) |
Perientheseal bone marrow oedema | 0 (0.0) | 2 (15.4) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 1 (14.3) |
Entheseal enhancement | 3 (42.9) | 4 (36.4) | 5 (71.4) | 2 (50.0) | 4 (66.7) | 0 (0.0) | 5 (45.5) | 8 (47.1) | 5 (62.5) |
Values are the number (percentage) of patients with a positive finding on MRI.
There were no significant differences in frequency of enthesitis between SpA and RA, neither when the knee and ankle MRI were analysed separately nor when the data of the knee and ankle joints were combined.
SpA, spondyloarthritis; RA, rheumatoid arthritis; CA, crystal arthropathy.